CAR-T Meeting 2022 | Rationale for using CAR-Ts to treat chronic hepatitis B
Ulrike Protzer, MD, Technical University of Munich, Munich, Germany, outlines the rationale behind using chimeric antigen receptor T-cells (CAR-Ts) for the treatment of hepatitis B and hepatitis B virus-associated liver cancer. Since viruses deposit proteins on the surface of infected cells, it is possible to design a CAR construct targeting this protein. In addition, upon infection, the hepatitis B virus persists in cells without immediately killing them, which makes it an interesting virus to target with a CAR-T. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
Disclosures
Share holder and board member of SCG Cell Therapy.
Ad hoc scientific advisor for AbbVie, Arbutus, Gilead, GSK, Johnson & Johnson, Roche, Sanofi, Sobi, and Vaccitech.
